Factual Explainer

Fix USA Plan · Health & Medicine evidence · reviewed August 22, 2026

ADHD, celiac disease, and pediatric GERD: current evidence baselines

These records separate population burden, standard-care context, experimental research, negative evidence, and trial lifecycle. They are educational evidence summaries, not diagnosis, treatment instructions, or claims that an experimental intervention is a cure.

Health & Medicine Current National Baselines Evidence & Corrections Methodology Home

ADHD population baseline

2024 diagnosed-ADHD prevalence among U.S. children

CDC/NCHS FastStats reports that 12.0% of U.S. children ages 3–17 had ever been diagnosed with ADHD in 2024. The reported figures were 15.6% for boys and 8.2% for girls.

Evidence stage: national health-survey prevalence estimate.

Limit: diagnosed prevalence is not an individual diagnostic tool, a severity measure, a causal explanation, a treatment recommendation, or a measure of durable remission.

Source: https://www.cdc.gov/nchs/fastats/adhd.htm · National Health Interview Survey, 2024.

Celiac disease: experimental immune-tolerance research and negative evidence

ACeD-it: a terminated adult KAN-101 program

ClinicalTrials.gov lists NCT05574010, a Phase 1b/2 adult celiac study of KAN-101, as terminated with the stated reason “Sponsor decision”. The registry reports actual enrollment of 128 and a last update/results posting on March 10, 2026.

What did not close: termination is important lifecycle evidence, but “sponsor decision” does not by itself prove lack of efficacy, toxicity, or failure of the underlying immune-tolerance mechanism.

Age/safety limit: the study enrolled adults ages 18–70. It should not be generalized to children. KAN-101 remains experimental; this record is not a treatment recommendation or cure claim.

Source: https://clinicaltrials.gov/study/NCT05574010 · NCT05574010.

SynCeD: a completed small adult Phase 2 registry result

ClinicalTrials.gov lists NCT06001177, the adult Phase 2 KAN-101/placebo SynCeD study, as completed, with study results posted December 18, 2025.

Promise vs. Proof: completion and posted sponsor-submitted results establish that the study reached a results-reporting stage; they do not establish durable immune tolerance, regulatory approval, clinical effectiveness for every endpoint, suitability for children, or cure.

Evidence-use rule: Fix USA Plan will not infer treatment benefit from a single registry outcome value without the prespecified statistical interpretation and full evidence context.

Source: https://clinicaltrials.gov/study/NCT06001177?tab=results · NCT06001177.

Pediatric GERD: care context and evidence limits

Current-care context is not the same as durable remission

NIDDK states that clinicians may use lifestyle changes, medicines, and in selected cases surgery for gastroesophageal reflux disease in children. It says proton-pump inhibitors are typically prescribed for 4 to 8 weeks and notes that studies of lifestyle changes in children are limited.

Safety: NIDDK explicitly advises not to use over-the-counter or prescription GERD medicines for a child unless directed by the child’s doctor. This page does not authorize starting, stopping, tapering, or changing a medicine, diet, device, test, or procedure.

Freshness limit: the NIDDK page was last reviewed in November 2020 and cites the 2018 NASPGHAN/ESPGHAN pediatric guideline. Fix USA Plan treats it as stable federal care-context evidence and requires a newer guideline/current-evidence check before making a high-stakes treatment claim.

Source: https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd-children/treatment

Mental health and addiction: current national burden and trend baselines

2025 adult mental-illness prevalence

SAMHSA’s 2025 National Survey on Drug Use and Health estimates that 54.6 million adults age 18 or older (20.6%) had any mental illness in the past year and 18.2 million (6.9%) had serious mental illness. The report says the percentage with any mental illness showed no overall change from 2021 to 2025, while serious mental illness declined from 7.9% to 6.9%.

Evidence stage: national population survey using model-based DSM-5-aligned definitions.

Limit: prevalence is not an individual diagnosis, a measure of treatment need or access, or evidence that a particular policy caused the trend.

Source: https://www.samhsa.gov/data/sites/default/files/NSDUH-2025-Annual-Release/2025-nsduh-nnr-highlights.pdf · July 2026.

Major depression and substance-use disorder can co-occur

SAMHSA reports that in 2025, 55.1 million adults had either a major depressive episode or a substance use disorder in the past year; 7.3 million (2.8%) had both. Separately, 19.7 million adults had a major depressive episode and 42.7 million had a substance use disorder.

Evidence stage: national population survey.

Limit: the 12-month co-occurrence measure does not establish that the conditions occurred at the same moment, which came first, or what treatment an individual should receive.

Source: https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-report.pdf · July 2026.

2025 provisional overdose deaths declined nationally, with important state variation

CDC/NCHS provisionally estimated 69,973 U.S. drug-overdose deaths during 2025, almost 14% below the estimated 81,313 in 2024. Estimated opioid-involved deaths declined from 55,296 to 44,564. CDC also reported that several states had declines of 25% or more while New Mexico, Arizona, and Colorado had increases of 10% or more.

Evidence stage: provisional mortality surveillance.

Limit: provisional counts are incomplete and subject to revision. A national decline does not mean every jurisdiction improved and does not establish the cause or effect of a specific treatment or policy.

Source: https://www.cdc.gov/nchs/pressroom/releases/20260513.html · May 13, 2026.

Longevity and healthy aging: final national mortality baselines

Final 2024 life expectancy at birth and at age 65

NCHS final mortality data report U.S. life expectancy at birth was 79.0 years in 2024, up from 78.4 in 2023. Life expectancy at age 65 was 19.7 years; it was 20.8 years for females and 18.4 years for males.

Evidence stage: final National Vital Statistics System mortality data.

Limit: life expectancy is a population summary shaped by many causes and groups. It is not evidence that an anti-aging intervention works and is not an individual prognosis.

Source: https://www.cdc.gov/nchs/data/databriefs/db548.pdf · January 29, 2026.

Final 2024 age-adjusted mortality declined

NCHS reports the U.S. age-adjusted death rate fell 3.8%, from 750.5 deaths per 100,000 in 2023 to 722.1 in 2024. Heart disease, cancer, and unintentional injuries remained the top three leading causes of death; suicide ranked 10th and COVID-19 ranked 15th.

Evidence stage: final National Vital Statistics System mortality data.

Limit: aggregate mortality changes do not establish the contribution of a particular policy, behavior, clinical intervention, or demographic shift and are not an individual risk assessment.

Source: https://www.cdc.gov/nchs/data/databriefs/db548.pdf · January 29, 2026.

Pediatric nutrition and cardiometabolic burden

Abnormal cholesterol among children and adolescents varies by weight status

NCHS Data Brief 552 reports 16.5% of U.S. children and adolescents ages 6–19 had at least one abnormal cholesterol measure in August 2021–August 2023. Prevalence was 10.3% among those with underweight or normal weight, 11.5% among those with overweight, and 35.8% among those with obesity. The overall prevalence declined from 21.3% in 2013–2014 to 16.5% in the latest period.

Evidence stage: measured NHANES cross-sectional national survey data.

Limit: the association is observational and does not prove that obesity caused an individual child’s lipid abnormality. This is not a diagnosis, treatment recommendation, or justification for stigmatizing children.

Source: https://www.cdc.gov/nchs/data/databriefs/db552.pdf · March 18, 2026.

How to read these health records

Population prevalence, current-care guidance, trial registration, trial completion, safety, biomarker change, symptom change, mortality trends, and durable remission answer different questions. Fix USA Plan keeps those evidence stages separate and includes negative or terminated research rather than displaying only favorable signals.

Freshness: review ADHD after the next relevant CDC/NCHS update; review celiac after material ClinicalTrials.gov, peer-reviewed, regulatory, or guideline updates; review pediatric GERD against newer pediatric GI guidance before any high-stakes treatment claim; review mental-health/addiction trends after the next NSDUH or NCHS surveillance update; review longevity and pediatric lipid baselines after new final NCHS/NHANES releases.